Pulse radiation may supercharge immunotherapy against cancer

This phase 2 trial is testing whether adding a special type of radiation called adaptive pulse radiotherapy to standard immunotherapy can help treat advanced solid tumors. The study will enroll 35 people who are already receiving or planning to receive immune checkpoint inhibitors. Participants will get 2-3 high-dose radiation sessions alongside their regular immunotherapy, with the radiation target adjusted based on tumor response. Researchers will monitor tumor shrinkage, survival, side effects, and quality of life.